217330.Kq

The company's capital structure is characterized by a debt-to-equity ratio of 0.46, indicating a relatively conservative leverage position compared to industry norms. However, the company's liquidity position is marked by a negative net cash position after subtracting total debt, which raises concerns about its ability to meet short-term obligations without external financing. The company's liquidity risk is assessed as medium, with a current ratio of 2.93, suggesting it has sufficient current assets to cover its current liabilities, but the negative operating cash flow of -6.95 billion KRW and free cash flow of -11.2 billion KRW indicate ongoing cash outflows that could strain liquidity in the near term.

Profitability metrics show the company is currently unprofitable, with a net loss of -12.34 billion KRW and an operating loss of -11.23 billion KRW. The return on equity (ROE) is -34.71%, and the return on assets (ROA) is -19.83%, both significantly below the industry median for biotechnology firms. The gross profit margin is 21.55%, which is in line with the industry average, but the operating margin is -43.1%, indicating substantial operational inefficiencies or high costs relative to revenue.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks, particularly in the healthcare diagnostics sector, where regulatory changes and competitive pressures can significantly impact revenue streams. The company's revenue concentration risk is high, as it relies on a single segment for all its income, and there is no indication of geographic diversification to mitigate regional economic or regulatory risks.

The company's growth trajectory is uncertain, with no disclosed revenue growth in the most recent fiscal year. The outlook for the current fiscal year is negative, with no expected improvement in revenue or profitability. The company's capital expenditures of -2.04 billion KRW suggest a reduction in investment in new projects or facilities, which could limit future growth opportunities. The company's free cash flow is negative, and there is no indication of a turnaround in the near term, which could hinder its ability to fund expansion or R&D initiatives.

The company's risk profile is elevated due to its negative net income and operating cash flow, which increase the likelihood of needing to raise additional capital. The dilution risk is assessed as low, with no significant dilution expected in the near term. However, the company's negative free cash flow and operating cash flow could necessitate future equity or debt financing, which could lead to dilution if not managed carefully. The company's risk assessment indicates a medium liquidity risk, with a current ratio of 2.93, but the negative operating cash flow and free cash flow suggest potential liquidity constraints.

Recent events, including the company's latest financial filing, show continued financial challenges, with no significant positive developments in the most recent quarter. The company's financial statements indicate ongoing losses and negative cash flows, which could impact investor confidence and access to capital markets. There are no recent transcripts or press releases indicating strategic changes or new product launches that could improve the company's financial position.